Anthera Pharmaceuticals News
Anthera Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Seeking Alpha May 20Anthera Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
PR Newswire May 13HAYWARD, Calif., May 13, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended March 31 st , 2013. First Quarter ...
Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
Benzinga May 7Anthera Announces First Quarter 2013 Financial Report and Conference Call
PR Newswire May 3HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will ...
Anthera Pharma (ANTH) Files $100M Mixed Shelf
Street Insider Apr 8Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
PR Newswire Apr 5HAYWARD, Calif., April 5, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced ...
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar 28Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
PR Newswire Mar 27HAYWARD, Calif., March 27, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune ...
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ANTH | 0.5949 | +0.01 | +2.57% | 88.58M |
